Your browser doesn't support javascript.
loading
Patients' treatment preferences for potentially resectable tumors of the head of the pancreas.
Molinari, Michele; El-Tawil, Karim; Swaid, Forat; Fiorentini, Guido; Bou-Samra, Patrick; Sharma, Chakshu; Liu, Hao; Rahman, Sheikh Hasibur; Hurton, Scott; Tsung, Allan.
Afiliação
  • Molinari M; University of Pittsburgh Medical Center, United States; The Queen Elizabeth II Medical Center, Dalhousie University, Halifax, Nova Scotia, Canada. Electronic address: molinarim@upmc.edu.
  • El-Tawil K; The Queen Elizabeth II Medical Center, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Swaid F; University of Pittsburgh Medical Center, United States.
  • Fiorentini G; University of Pittsburgh Medical Center, United States.
  • Bou-Samra P; University of Pittsburgh Medical Center, United States.
  • Sharma C; The Queen Elizabeth II Medical Center, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Liu H; University of Pittsburgh Medical Center, United States.
  • Rahman SH; University of Western Ontario Ringgold standard institution - Medicine, London, Ontario N6A 3K7, Canada.
  • Hurton S; The Queen Elizabeth II Medical Center, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Tsung A; University of Pittsburgh Medical Center, United States.
HPB (Oxford) ; 22(2): 265-274, 2020 02.
Article em En | MEDLINE | ID: mdl-31501009
ABSTRACT

BACKGROUND:

The primary aim of this study was to assess if patients with potentially resectable ductal adenocarcinoma (PDAC) of the head of the pancreas would choose a Whipple procedure versus palliative chemotherapy.

METHODS:

A cohort of adults with radiological resectable PDAC was enrolled at a tertiary Canadian teaching hospital. Participants were informed about treatment options, expected outcomes, and adverse events using data from the most recent scientific literature. Probability trade-off (PTO) was used to elicit treatment preferences.

RESULTS:

Surgery was preferred by all participants except one (96.7% vs. 3.3%; P = 0.0001). For 90% of participants preferring surgery, the main reason was the hope of being cured (P = 0.001). If the risk of perioperative mortality was higher than 57%, the risk of perioperative morbidity higher than 85% and the survival benefit was less than 4 months, half of the participants preferred palliative chemotherapy. The likelihood of needing blood transfusions, the length of hospital stay, and long-term consequences such as diabetes or pancreatic exocrine insufficiency were negligible concerns to participants.

CONCLUSIONS:

Informed patients with early-stage PDAC prefer resection over palliative chemotherapy. The dominating factor influencing their decision is the hope of a cure that overshadow the risks of complications, mortality and recurrent disease.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Preferência do Paciente Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: HPB (Oxford) Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático / Preferência do Paciente Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: HPB (Oxford) Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2020 Tipo de documento: Article